- Home
- TYRA vs STDN Comparison
TYRA vs STDN Comparison
Compare TYRA & STDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TYRA | STDN |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | TYRA | STDN |
|---|---|---|
| Price | $26.04 | $10.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $47.50 | N/A |
| AVG Volume (30 Days) | 630.1K | ★ 945.0K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $7.05 |
| 52 Week High | $40.65 | $11.28 |
Technical Indicators
Market Signals| Indicator | TYRA | STDN |
|---|---|---|
| Relative Strength Index (RSI) | 34.50 | 50.53 |
| Support Level | $24.77 | $8.19 |
| Resistance Level | $32.82 | N/A |
| Average True Range (ATR) | 1.75 | 0.83 |
| MACD | -0.67 | 0.17 |
| Stochastic Oscillator | 7.53 | 82.26 |
Price Performance
Historical ComparisonAbout TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.